Abstract Treatment resistant schizophrenia (TRS) refers to the significant proportion of
schizophrenia patients who continue to have symptoms and poor outcomes despite …

Background Schizophrenia is a highly heterogeneous disorder, and around a third of
patients are treatment-resistant. The only evidence-based treatment for these patients is …

To remember what one did yesterday is an example of an everyday episodic memory task,
in which a female advantage has sometimes been reported. Here, we quantify the impact of …

Although treatment-resistant schizophrenia (TRS) was described 50 years ago 1 and has a
gold standard treatment with clozapine based on well-defined criteria, 2 there is still a matter …

Almost fifty years after its first introduction into clinical care, clozapine remains the only
evidence-based pharmacological option for treatment-resistant schizophrenia (TRS), which …

The aim of this work was to compare achievements in milestones of community functioning
in highly disabling psychiatric conditions, including treatment resistant schizophrenia (TRS) …

Importance About 20% to 30% of people with schizophrenia have psychotic symptoms that
do not respond adequately to first-line antipsychotic treatment. This clinical presentation …

Treatment-resistant schizophrenia, affecting approximately 20–30% of patients with
schizophrenia, has a high burden both for patients and healthcare services. There is a need …

In mammals, early adverse experiences, including mother–pup interactions, shape the
response of an individual to chronic stress or to stress-related diseases during adult life. This …

Objective: Failure of antipsychotic medications to resolve symptoms in patients with
schizophrenia creates a clinical challenge that is known as treatment resistance. The causes …